These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33564429)

  • 1. Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study.
    Kielstein JT; Heisterkamp M; Jing J; Nadal J; Schmid M; Kronenberg F; Busch M; Sommerer C; Lorenzen JM; Eckardt KU; Köttgen A;
    Clin Kidney J; 2021 Jan; 14(1):277-283. PubMed ID: 33564429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study.
    Jing J; Kielstein JT; Schultheiss UT; Sitter T; Titze SI; Schaeffner ES; McAdams-DeMarco M; Kronenberg F; Eckardt KU; Köttgen A;
    Nephrol Dial Transplant; 2015 Apr; 30(4):613-21. PubMed ID: 25395390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy.
    Pascart T; Latourte A; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
    Joint Bone Spine; 2020 Oct; 87(5):395-404. PubMed ID: 32422338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing.
    Schulz M; Coleshill MJ; Day RO; Wright DFB; Brett J; Briggs NE; Aung E
    Br J Clin Pharmacol; 2024 May; 90(5):1322-1332. PubMed ID: 38382554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
    Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
    Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials.
    Liu X; Qiu Y; Li D; Tan J; Liang X; Qin W
    Front Pharmacol; 2021; 12():690557. PubMed ID: 34413775
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of Xanthine Oxidase Inhibitors in Lowering Serum Uric Acid in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
    Lee Y; Hwang J; Desai SH; Li X; Jenkins C; Kopp JB; Winkler CA; Cho SK
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.
    Helget LN; Davis-Karim A; O'Dell JR; Mikuls TR; Newcomb JA; Androsenko M; Brophy MT; England BR; Ferguson R; Pillinger MH; Neogi T; Wu H; Palevsky PM
    Am J Kidney Dis; 2024 Jun; ():. PubMed ID: 38906504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease.
    Kim Y; Shin S; Kim K; Choi S; Lee K
    J Rheumatol; 2015 Nov; 42(11):2143-8. PubMed ID: 26428209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
    Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
    PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation.
    Holladay EE; Mudano AS; Xie F; Zhang J; Mikuls TR; LaMoreaux B; Padnick-Silver L; Curtis JR
    Arthritis Res Ther; 2024 Apr; 26(1):86. PubMed ID: 38609967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    Jackson RL; Hunt B; MacDonald PA
    BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.
    Perez-Ruiz F; Atxotegi J; Hernando I; Calabozo M; Nolla JM
    Arthritis Rheum; 2006 Oct; 55(5):786-90. PubMed ID: 17013833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.